SCHEMBL3222839

SCHEMBL3222839

Clc1cccc(Cl)c1OC1CCNCC1

nearest known ligand 0.66

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 14/20 0.66
HTR1A P08908 12/20 0.66
SLC6A4 P31645 7/20 0.66
HRH1 P35367 3/20 0.53
SLC6A3 Q01959 6/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363791 0.88 HTR1A (0.58) SLC6A2HTR1ASLC6A4HRH1SLC6A3
SCHEMBL3080032 0.80 SLC6A2 (0.57) SLC6A2HTR1ASLC6A4HRH1SLC6A3
SCHEMBL2299492 0.80 SLC6A2 (0.64) SLC6A2HTR1ASLC6A4SLC6A3
SCHEMBL82955 0.79 HRH1 (0.62) SLC6A2HTR1ASLC6A4HRH1SLC6A3
Hydrochloric Acid SCHEMBL4095144 0.79 SLC6A2 (0.56) SLC6A2HTR1ASLC6A4HRH1SLC6A3
Hydrochloric Acid SCHEMBL69459 0.78 HRH1 (0.60) SLC6A2HTR1ASLC6A4HRH1SLC6A3
SCHEMBL22278138 0.78 SLC6A2 (0.62) SLC6A2HTR1ASLC6A4HRH1SLC6A3
SCHEMBL18367733 0.77 SLC6A2 (0.47) SLC6A2HTR1ASLC6A4SLC6A3
SCHEMBL31053713 0.77 SLC6A2 (0.47) SLC6A2HTR1ASLC6A4SLC6A3
SCHEMBL29003883 0.77 SLC6A2 (0.71) SLC6A2HTR1ASLC6A4HRH1SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4674416-A1 PROTEIN AGGREGATE DECOMPOSITION PROMOTING COMPOSITION AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH PROTEIN AGGREGATE FORMATION NAGASAKI UNIVERSITY (JP) 2026-01-07 EP disclosed
WO-2024181431-A1 PROTEIN AGGREGATE DECOMPOSITION PROMOTING COMPOSITION AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH PROTEIN AGGREGATE FORMATION 国立大学法人 長崎大学 2024-09-06 WO disclosed
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 US disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 US disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 US disclosed
WO-2007092435-A2 11-BETA HSD1 INHIBITORS WYETH (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029648-A1 11-Beta HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 SLC6A2 2676/4885HTR1A 484/4885SLC6A4 1538/4885
US-20070219198-A1 11-Beta HSD 1 inhibitors HSD11B1, HSD11B2, HSD3B1 SLC6A2 1873/4885HTR1A 264/4885SLC6A4 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.